$NeuroBo Pharmaceuticals, Inc.

2020-04-14

$NeuroBo Pharmaceuticals, Inc.(NRBO)$BOSTON, April 14, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale in a registered direct offering of 750,000 shares of the Company's common stock, at a purchase price of $10.00 per share. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":928450009,"tweetId":"928450009","gmtCreate":1586873122901,"gmtModify":1705302174841,"author":{"id":3490591417137744,"idStr":"3490591417137744","authorId":3490591417137744,"authorIdStr":"3490591417137744","name":"联合国收割机","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":561,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NRBO\">$NeuroBo Pharmaceuticals, Inc.(NRBO)$</a>BOSTON, April 14, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale in a registered direct offering of 750,000 shares of the Company's common stock, at a purchase price of $10.00 per share. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NRBO\">$NeuroBo Pharmaceuticals, Inc.(NRBO)$</a>BOSTON, April 14, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale in a registered direct offering of 750,000 shares of the Company's common stock, at a purchase price of $10.00 per share. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.</p></body></html>","text":"$NeuroBo Pharmaceuticals, Inc.(NRBO)$BOSTON, April 14, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale in a registered direct offering of 750,000 shares of the Company's common stock, at a purchase price of $10.00 per share. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/928450009","repostId":0,"isVote":1,"tweetType":1,"viewCount":399,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NRBO"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":606,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/928450009"}